
Please try another search
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Javed Butler | - | 2023 | Member of PH-HFpEF Scientific Advisory Board |
Gerald T. Proehl | 66 | 2014 | Independent Chairman |
Stuart Rich | 75 | 2018 | Chief Medical Officer & Director |
Michael Harvey Davidson | 69 | 2021 | Independent Director |
Declan Doogan | 73 | 2021 | Independent Director |
Christopher T. Giordano | 50 | 2021 | CEO, President & Director |
Barry Borlaug | - | 2020 | Member of Scientific Advisory Board |
Daniel Burkhoff | - | 2018 | Member of Scientific Advisory Board |
Sanjiv J. Shah | - | 2018 | Chairman of Scientific Advisory Board |
June S. Almenoff | 68 | 2021 | Independent Director |
Robyn M. Hunter | 63 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review